Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2022 Earnings Call Transcript

Page 11 of 11

Kate Haviland: Thank you, operator. And really, as we kind of come out of the Q&A and taking a step back, I mean, today, we have highlighted the significant opportunities that we have as Blueprint right in front of us, to create value for patients and for our shareholders, including our continued commercial execution, our anticipated launch in ISM, as well as the ambitious and achievable goals we have for our pipeline. And we are confident in our ability to deliver on these opportunities this year and beyond. We thank you all for taking the time and joining us today and your continued support of Blueprint Medicines. And we look forward to talking to you again soon this time from San Antonio in the Quad AI conference. So looking forward to it.

Operator: That concludes today’s Blueprint Medicines 4Q and FY 2022 earnings call. You may now disconnect your line.

Follow Blueprint Medicines Corp (NASDAQ:BPMC)

Page 11 of 11